GSK plc (LON:GSK) Stock Has Consensus Price Target of GBX 2,064.38

GSK plc (LON:GSK) has earned an average recommendation of “Hold” from the eight brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 2,064.38.

A number of equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Tuesday, September 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research report on Tuesday, October 20th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 1,975 target price on shares of GSK in a research report on Tuesday, September 8th. Finally, Berenberg Bank increased their price target on GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research report on Tuesday, September 15th.

Insider Transactions at GSK

In other news, insider Anne Beal purchased 637 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The stock was acquired at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the business’s stock in a transaction on Friday, September 18th. The stock was acquired at an average cost of GBX 1,881 per share, with a total value of £28,215. Insiders have purchased 2,151 shares of company stock valued at $6,021,921 in the last quarter. 0.20% of the stock is currently owned by corporate insiders.

GSK Price Performance

LON:GSK opened at GBX 1,894 on Friday. The firm has a market cap of £75.89 billion, a PE ratio of 16.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK has a 12 month low of GBX 1,592 and a 12 month high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36. The company’s 50-day moving average price is GBX 1,847.39 and its two-hundred day moving average price is GBX 1,918.60.

GSK (LON:GSK) last released its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities analysts anticipate that GSK will post 175.98 EPS for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.